Aligos Therapeutics, Inc.ALGSNASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
|
|
|
|

Operating cash flow minus capital expenditures

Latest
$-80.87M
↓ 15% below average
Average (6y)
$-70.17M
Historical baseline
Range
High:$-8.56M
Low:$-116.55M
CAGR
+45.4%
Consistent expansion
PeriodValueChange
2024$-80.87M-2.4%
2023$-79.02M+1.6%
2022$-80.33M+31.1%
2021$-116.55M-52.7%
2020$-76.33M-54.0%
2019$-49.55M-478.6%
2018$-8.56M-